Sam Freeman

Title: Sam Freeman: Innovator in Cancer Treatment

Introduction

Sam Freeman is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of cancer research and treatment. His innovative work focuses on the identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms.

Latest Patents

Freeman holds a patent for "Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms." This invention relates to methods for identifying, assessing, preventing, and treating various cancers, including head, neck, and lung cancers in humans. The patent provides a variety of PD-L1 isoform biomarkers, wherein alterations in the copy number or activity of these biomarkers are associated with cancer status. This indicates the potential for treatment or prevention by modulating PD-1 and/or PD-L1 levels.

Career Highlights

Sam Freeman is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance cancer research. His work has been instrumental in developing new methodologies that enhance the understanding of cancer biology and treatment options.

Collaborations

Freeman collaborates with esteemed colleagues, including Peter Hammerman and Matthew Meyerson. These partnerships foster a collaborative environment that enhances research outcomes and innovation in cancer treatment.

Conclusion

Sam Freeman's contributions to cancer research through his innovative patent demonstrate his commitment to improving treatment options for patients. His work at the Dana-Farber Cancer Institute Inc. and collaborations with other experts highlight the importance of teamwork in advancing medical science.